FDA Advisors to Mull New Methods of Communicating REMS Risk Information

Drug Industry Daily
A A
The FDA is seeking input on the effectiveness of risk evaluation and mitigation strategy (REMS) programs as it weighs whether new methods of communicating drug risks in REMS are needed.

To View This Article:

Login

Subscribe To Drug Industry Daily